微创机器人-B今日盘中股价大幅上涨6.53%，引起了市场的广泛关注。
消息面上，近期手术机器人领域政策支持持续加码，北京市医保局等十部门发布措施推动手术机器人入院，湖南省医保局也明确了相关收费标准，为行业发展注入强心剂。
公司层面利好频传，瑞银发布研报将其评级由“中性”上调至“买入”，目标价大幅上调至35.9港元，并预计公司未来三年收入将高速增长。同时，公司自主研发的鸿鹄骨科手术机器人成功获得欧洲CE认证，成为国内首款获此认证的关节置换手术机器人，标志着其产品国际化取得重要突破。此外，公司核心产品“图迈”手术机器人去年销量增长超五倍，海外收入同比大增287%，公司目标今年总收入实现翻倍，并有望于上半年达到收支平衡。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.